Business
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -","length":124,"tagName":"p"},{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.","length":562,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":369,"url":"https://media.zenfs.com/en/accesswire.ca/8bdfa1d72f79a3dab13657f9804fc698"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ASbi50diVolX7njw3hrnKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/8bdfa1d72f79a3dab13657f9804fc698","width":624,"height":369}},"href":"https://app.accessnewswire.com/imagelibrary/0f920caf-9e97-49dd-af09-ae2953417c31/1129914/igcpharma-logo.jpg","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System ("CNS") disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.","length":431,"tagName":"p"},{"type":"text","content":""Adding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders," said Ram Mukunda, CEO of IGC Pharma. "Their experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1."","length":377,"tagName":"p"},{"type":"text","content":...